{"created":"2023-06-20T15:49:12.164056+00:00","id":3772,"links":{},"metadata":{"_buckets":{"deposit":"b7598fb1-da06-4fae-b908-bf0541e42aad"},"_deposit":{"created_by":4,"id":"3772","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"3772"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00003772","sets":["1:11"]},"author_link":[],"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-07-10","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"397","bibliographicPageStart":"389","bibliographicVolumeNumber":"335","bibliographic_titles":[{"bibliographic_title":"Journal of Controlled Release ","bibliographic_titleLang":"en"}]}]},"item_3_description_10":{"attribute_name":"注記","attribute_value_mlt":[{"subitem_description":"＜参照＞出版社サイト:https://doi.org/10.1016/j.jconrel.2021.05.027 ","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"As current treatments for multiple sclerosis (MS) remain chemotherapeutic ones directed toward symptoms, the development of a curative treatment is urgently required. Herein, we show an autoreactive immune celltargetable approach using autoantigen-modified liposomes for the curative treatment of MS. In these experiments, experimental autoimmune encephalomyelitis (EAE) induced by autoantigenic myelin oligodendrocyte glycoprotein (MOG) peptide was used as a model of primary progressive MS, and MOG-modified liposomes encapsulating doxorubicin (MOG-LipDOX) were used as a therapeutic drug. The results showed that the progression of encephalomyelitis symptoms was significantly suppressed by MOG-LipDOX injection, whereas the other samples failed to show any effect. Additionally, invasion of inflammatory immune cells into the spinal cord and demyelination of neurons were clearly suppressed in the MOG-LipDOX-treated mice. FACS analysis revealed that the number of both MOG-recognizable CD4+ T cells in the spleen was obviously decreased after MOGLipDOX treatment. Furthermore, the number of effector Th17 cells in the spleen was significantly decreased and that of regulatory Treg cells was concomitantly increased. Finally, we demonstrated that myelin proteolipid protein (PLP)-modified liposomes encapsulating DOX (PLP-LipDOX) also showed the therapeutic effect on relapsing-remitting EAE. These findings indicate that autoantigen-modified liposomal drug produced a highly therapeutic effect on EAE by delivering the encapsulated drug to autoantigen-recognizable CD4+ T cells and thus suppressing autoreactive immune responses. The present study suggests that the use of these autoantigenmodified liposomes promises to be a suitable therapeutic approach for the cure of MS.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier ","subitem_publisher_language":"en"}]},"item_3_relation_26":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"34033858","subitem_relation_type_select":"PMID"}}]},"item_3_relation_28":{"attribute_name":"出版社DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.jconrel.2021.05.027","subitem_relation_type_select":"DOI"}}]},"item_3_relation_34":{"attribute_name":"出版社版","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1016/j.jconrel.2021.05.027","subitem_relation_type_select":"DOI"}}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright 2021 Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/","subitem_rights_language":"en"},{"subitem_rights":"This is the Published journal article version. The formal published version is available at \"https://doi.org/10.1016/j.jconrel.2021.05.027\".","subitem_rights_language":"en"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0168-3659","subitem_source_identifier_type":"PISSN"}]},"item_3_source_id_20":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"1873-4995","subitem_source_identifier_type":"EISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Shimizu, Kosuke","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Agata, Kazuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takasugi, Shohei","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Goto, Shungo","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Narita, Yudai","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Asai, Tomohiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Magata, Yasuhiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Oku, Naoto","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-10-05"}],"displaytype":"detail","filename":"JCR-335-389.pdf","filesize":[{"value":"8.1 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"JCR-335-389.pdf","url":"https://hama-med.repo.nii.ac.jp/record/3772/files/JCR-335-389.pdf"},"version_id":"fe77e996-d04a-4292-97e9-665166ffafc6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Autoantigen-modified liposome","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Autoantigen-recognizing T cell","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Experimental autoimmune encephalomyelitis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Multiple sclerosis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Spleen","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Targeting","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect","subitem_title_language":"en"}]},"item_type_id":"3","owner":"4","path":["11"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-10-05"},"publish_date":"2021-10-05","publish_status":"0","recid":"3772","relation_version_is_last":true,"title":["New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-09-21T05:04:08.306644+00:00"}